Introduction of European Union Pharmacovigilance System facing New Regulation

Abstract

Abstract: By introducing the revision of European Union(EU) Pharmocovigilance regulation, it helped to know the structure of EU Pharmacovigilance system better. And it also clearly showed the contents of the system, such as Pharmacovigilance Systems and their Quality Systems, Pharmacovigilance System Master File, Pharmacovigilance Inspections, Risk Management Systems. It provided the example and reference for perfecting and developing Adverse Drug Reaction Reporting and Monitoring System of China.

Key words: European Union, new regulation, pharmacovigilance, system

DONG Duo, WU Gui-zhi, CHENG Gang. Introduction of European Union Pharmacovigilance System facing New Regulation[J]. Chinese Journal of Pharmacovigilance, 2012, 9(11): 662-665.

References

[1] European Commission. The EU pharmacovigilance system[EB/OL].http://ec.europaeu/health/human-use/pharmacovigilance/index_en.htm#geninf（2012-09-16）.
[2] Peter Arlett. New Pharmacovigilance legislation and focus on post-authorisation studies (2010-11-29)[EB/OL].www.diahome.org/.../24003/session%203_peter%20arlett.pdf (2012-9-16).
[3] European Medicines Agency. 2010 pharmacovigilance legislation [EB/OL].http://www.ema.europa.eu/ema/index.jsp curl=pages/
regulation/general/general_content_000492.jsp&mid=WC0b01ac
4 058033e8ad (2012-9-16).
[4] European Medicines Agency. Commission Implementing Regulation (EU) No 520/2012（2012-6-19）[EB/OL]. http://eurx.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:159:0005:0025:EN:PDF （2012-9-16）.
[5] European Medicines Agency. Good Pharmacovigilance Practices [EB/OL].http://www.ema.europa.eu/ema/index.jsp curl=pages/
regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c（2012-9-16）.
[6] European Medicines Agency. GVP Module I Pharmacovigilance Systems and their Quality Systems（2012-6-22）[EB/OL].http://
www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129132.pdf（2012-09-17）.
[7] European Medicines Agency. GVP Module II Pharmacovigilance System Master File（2012-6-22）[EB/OL].http://www.ema.europa.
eu/docs/en_GB/document_library/Scientific_guideline/2012/06/
8 WC500129133.pdf（2012-09-17）.
[8] European Medicines Agency. GVP Module III Pharmacovigilance Inspections（2012-6-22）[EB/OL].http://www.ema.europa.eu/docs/en_
GB/document_library/Scientific_guideline/2012/06/WC500129243.
9 pdf（2012-09-17）.
[9] 董铎, 孙利华, 杨晓茹. 欧盟药物警戒检查制度简介[J].中国新药杂志, 2012,21 (9): 956-958.
[10] European Medicines Agency. GVP Module V- Risk Management Systems（2012-6-22）[EB/OL].http://www.ema.europa.eu/docs/en_
GB/document_library/Scientific_guideline/2012/06/WC500129134.pdf（2012-9-18）.
[11] European Medicines Agency. GVP Module VI - Management and Reporting of Adverse Reactions to Medicinal Products（2012-06-
22）[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2012/06/WC500129135.pdf（2012-
12 09-18）.
[12] 董铎, 孙利华, 刘巍. 药品生产企业定期安全性更新报告的准备[J]. 中国医药工业杂志, 2011,43 (3): 239-240.
[13] European Medicines Agency. GVP Module VII - Periodic Safety Update Reports（2012-6-22）[EB/OL].http://www.ema.europa.eu/
docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129136.pdf（2012-9-18）.
[14] 董铎, 孙利华, 王丹.从欧盟上市后安全性研究看我国药品重点监测的实施[J].中国医药工业杂志, 2011,43 (5): 399-A52.
[15] European Medicines Agency. GVP Module VIII - Post-Authorisation Safety Studies（2012-6-22）[EB/OL].http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/
WC500129137.pdf（2012-9-18）.
[16] European Medicines Agency. GVP Module IX - Signal Management（2012-6-22）[EB/OL].http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2012/06/WC500129138.pdf.
[17] European Medicines Agency. Pharmacovigilance Risk Assessment Committee(PRAC)[EB/OL].http://www.ema.europa.eu/ema/index.jsp curl=pages/about_us/general/general_content_000537.jsp&mid=
WC0b01ac058058cb18（2012-09-18）.
[18] European Medicines Agency. GVP Module XV Safety communication draft（2012-7-26）[EB/OL].http://www.ema.europa.eu/docs/
en_GB/document_library/Scientific_guideline/2012/07/WC500130396.
19 pdf(2012-9-18).
[19] Food and Drug Administration. Food and Drug Administration Amendments Act (2007) [EB/OL].
http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi dbname=
20 110_cong_public_laws&docid=f:publ085.110(2012-09-18).
[20] 颜敏, 兰奋, 叶国庆.《 ADR 报告和监测管理办法》修订要点和释义（J）. 药物流行病学杂志,2011,(20) 6: 273-274. （